NewsRx

Search our medical news database

Finance

Biopharma company receives $8 million cash payment on Estrasorb

Published in Women's Health Weekly, January 26th, 2006

Novavax, Inc. (NVAX) announced that it has received the second cash payment in the amount of $8 million related to its license agreement with Esprit Pharma, Inc.

Cash payments received to-date under the recently executed agreement for the exclusive marketing rights to Estrasorb in North America now total $10.0 million. Novavax will receive another $2.5 million from Esprit Pharma, Inc. upon the first anniversary of the agreement.

With the receipt of these funds announced today, the company's cash balance available for use in its 2006 business plan will be approximately $30 million as of year-end 2005.

Novavax, Inc. is a product...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook